Montelukast Cinfa (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Cinfa, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed in the maintenance therapy of asthma and for the relief of symptoms associated with seasonal and perennial allergic rhinitis in adults and children.

GNH USA supplies Montelukast Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Cinfa acts on the leukotriene pathway to control chronic airway and nasal inflammation.

- Asthma: reduces the frequency of bronchospasm episodes and improves overall asthma control. - Seasonal allergic rhinitis: alleviates nasal congestion, sneezing and itching during pollen seasons. - Perennial allergic rhinitis: provides sustained relief of nasal symptoms year‑round.

Montelukast Cinfa may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Hepatic injury - Suicidal thoughts or other neuropsychiatric events - Anaphylaxis

Before initiating therapy, clinicians should consider several safety aspects.

- Assess asthma control: ensure baseline control before adding Montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to Montelukast or any excipients. - Review concomitant medications for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast Cinfa can interact with other medicines that affect its metabolism or leukotriene pathways.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that may reduce Montelukast exposure and effectiveness. - Phenobarbital: enzyme inducer that can lower plasma concentrations of Montelukast.

Moderate Interactions (Monitor Closely): - Ketoconazole: CYP3A4 inhibitor that may increase Montelukast levels. - Fluconazole: moderate CYP3A4 inhibitor, may raise exposure. - Zafirlukast: concurrent leukotriene receptor blockade can increase risk of adverse effects.